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Abstract: Structural and biochemical studies have recently revealed a range of rationally engineered
nanobodies with efficient neutralizing capacity against the SARS-CoV-2 virus and resilience against
mutational escape. In this study, we performed a comprehensive computational analysis of the
SARS-CoV-2 spike trimer complexes with single nanobodies Nb6, VHH E, and complex with VHH
E/VHH V nanobody combination. We combined coarse-grained and all-atom molecular simulations and collective dynamics analysis with binding free energy scanning, perturbation-response
scanning, and network centrality analysis to examine mechanisms of nanobody-induced allosteric
modulation and cooperativity in the SARS-CoV-2 spike trimer complexes with these nanobodies.
By quantifying energetic and allosteric determinants of the SARS-CoV-2 spike protein binding with
nanobodies, we also examined nanobody-induced modulation of escaping mutations and the effect
of the Omicron variant on nanobody binding. The mutational scanning analysis supported the notion
that E484A mutation can have a significant detrimental effect on nanobody binding and result in
Omicron-induced escape from nanobody neutralization. Our findings showed that SARS-CoV-2
spike protein might exploit the plasticity of specific allosteric hotspots to generate escape mutants
that alter response to binding without compromising activity. The network analysis supported these
findings showing that VHH E/VHH V nanobody binding can induce long-range couplings between
the cryptic binding epitope and ACE2-binding site through a broader ensemble of communication
paths that is less dependent on specific mediating centers and therefore may be less sensitive to mutational perturbations of functional residues. The results suggest that binding affinity and long-range
communications of the SARS-CoV-2 complexes with nanobodies can be determined by structurally
stable regulatory centers and conformationally adaptable hotspots that are allosterically coupled and
collectively control resilience to mutational escape.
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SARS-CoV-2 infection is transmitted when the viral spike (S) glycoprotein binds to
the host cell receptor ACE2, leading to the entry of S protein into host cells and membrane
fusion [1,2]. The full-length SARS-CoV-2 S protein consists of amino (N)-terminal S1 subunit
and carboxyl (C)-terminal S2 subunit where S1 is involved in the interactions with the host
receptor and includes an N-terminal domain (NTD), the receptor-binding domain (RBD),
and two structurally conserved subdomains (SD1 and SD2). Structural and biochemical
studies established that the mechanism of virus infection may involve conformational
transitions between distinct functional forms of the SARS-CoV-2 S protein in which the
RBDs continuously switch between “down” and “up” positions [3–12]. The SARS-CoV-2
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antibodies are divided into several main classes, of which class 1 and class 2 antibodies
target epitopes that overlap with the ACE2 binding site [13–15]. The body of structural
and biochemical studies of the SARS-CoV-2 S complexes with different classes of potent
antibodies targeting distinct binding epitopes of the S-RBD as well as various antibody
cocktails and combinations have revealed multiple conformation-dependent epitopes,
highlighting the link between conformational plasticity and adaptability of S proteins and
capacity for eliciting specific binding and broad neutralization responses [16–32]. These
studies have examined SARS-CoV-2 S binding with antibodies showing that combinations
of antibodies can provide efficient cross-neutralization effects through synergistic targeting
of conserved and variable SARS-CoV-2 RBD epitope. Structural studies confirmed that the
SARS-CoV-2 S protein could feature distinct antigenic sites, and some specific antibodies
may allosterically inhibit the ACE2 receptor binding without directly interfering with ACE2
recognition [29]. Optimally designed antibody cocktails simultaneously targeting different
binding epitopes on the SARS-CoV-2 RBD also demonstrated improved resilience against
mutational escape [33–35].
Nanobodies or single-domain antibodies provide important advantages over traditional antibodies, including their smaller size and robust biochemical properties such as
high thermal stability, high solubility, and ability to be bioengineered into novel multivalent, multi-specific, and high-affinity molecules, making them a class of emerging
powerful therapies against SARS-CoV-2 [36–41]. Recent research efforts in the design, engineering, and structure-functional characterization of nanobodies and their binding with
SARS-CoV-2 S proteins reflect a growing realization that nanobody combinations could
deliver a powerful array of neutralizing and escape mutation resistant molecular assemblies capable of rationally exploiting distinct binding epitopes and the intrinsic plasticity
of the SARS-CoV-2 S protein. Structural aspects and classification of the nanobodies binding with the SARS-CoV-2 S were recently discussed in a review [42], highlighting several
classes of high-affinity nanobodies
An ultra-potent synthetic nanobody, Nb6, neutralizes SARS-CoV-2 by stabilizing
the fully inactive down S conformation preventing binding with ACE2 receptor [43]. A
high-affinity trivalent nanobody, mNb6-tri, can simultaneously bind to all three RBDs
and inhibit the interactions with the host receptor by occupying the binding site and locking the S protein in the inactive state [43]. The size-exclusion chromatography and mass
spectrometry revealed high-affinity RBD-targeting nanobodies that efficiently neutralize
SARS-CoV-2 by using several distinct and non-overlapping epitopes [44]. The revealed
dominant epitope targeted by Nb20 and Nb21 nanobodies overlaps with the ACE2 binding
site, showing that these nanobodies could competitively inhibit ACE2 binding and exploit
structural mimicry to facilitate conformational changes that prematurely convert spike
into a post-fusion state suppressing viral fusion [44]. Potent neutralizing nanobodies that
resist circulating variants of SARS-CoV-2 by targeting novel epitopes were recently discovered [45]. The reported cryo-EM structures for different classes of nanobodies suggested
mechanisms of high-affinity and broadly neutralizing activity by exploiting epitopes that
are shared with antibodies as well as novel epitopes that are unique to the nanobodies [45].
The high-affinity nanobodies against SARS-CoV-2 S protein refractory to common escape
mutants and exhibiting synergistic neutralizing activity are characterized by proximal but
non-overlapping epitopes showing that multimeric nanobody combinations can improve
potency while minimizing susceptibility to escape mutations [46]. These studies identified a
group of common resistant mutations in the dynamic RBM region (F490S, E484K, Q493K/R,
F490L, F486S, F486L, and Y508H) that evade many individual nanobodies. Structural
versatility of nanobody combinations that can effectively insulate the S-RBD accessible
regions suggested a mechanism of resistance to mutational escape in which combining two
nanobodies can markedly reduce the number of allowed substitutions to confer resistance
and thereby elevate the genetic barrier for escape [46,47]. Using human VH-phage library
and protein engineering, several unique VH binders were discovered that recognized two
separate epitopes within the ACE2 binding interface with nanomolar affinity [47]. Multiva-
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lent and bi-paratopic VH constructs showed markedly increased affinity and neutralization
potency to the SARS-CoV-2 virus when compared to the standalone VH domain [47]. Using
saturation mutagenesis of the RBD exposed residues combined with fluorescence-activated
cell sorting for mutant screening, escape mutants were identified for five nanobodies and
were mostly mapped to the periphery of the ACE2 binding site, with K417, D420, Y421,
F486, and Q493 emerging as notable hotspots [48]. A wide range of rationally engineered
nanobodies with efficient neutralizing capacity and resilience against mutational escape
was recently unveiled that included the llama-derived nanobody VHH E bound to the
ACE2- binding epitope and three alpaca-derived nanobodies, VHHs U, V, and W, that bind
to a different cryptic RBD epitope [49]. Using X-ray crystallography and surface plasmon
resonance-based binding competition, this study showed that combinations of nanobodies targeting distinct epitopes could suppress the escape mutants resistant to individual
nanobodies, while the bi-paratopic VHH EV and VE nanobodies with two antigen-binding
sites appeared to be even more effective than pairs VHH E+U, E+V, and E+W in preventing
mutual escape [40,41,49]. Using single-domain antibody library and PCR-based maturation,
two closely related and highly potent nanobodies, H11-D4 and H11-H4, were reported
that recognize the same epitope immediately adjacent to and partly overlapping with the
ACE2 binding region [50]. The crystal structures of these nanobodies bound to the S-RBD
revealed binding to the same epitope, which partly overlaps with the ACE2 binding surface,
explaining competitive inhibition of ACE2 interactions. These studies demonstrated that
nanobodies might have potential clinical applications due to the increased neutralizing
activity and robust protection against escape mutations of SARS-CoV-2.
The high-affinity nanobody cocktails of two noncompeting nanobodies can neutralize both wild-type SARS-CoV-2 and the variants [51]. Neutralization of SARS-CoV-2 by
low-picomolar and mutation-tolerant VHH nanobodies that bind synergistically to the
opposite sides of the RBD produced a binding avidity effect unaffected by immune-escape
mutants K417N/T, E484K, N501Y, and L452R [52]. The nanobody cocktails from camelid
mice and llamas that neutralize SARS-CoV-2 variants showed a remarkable ability of multivalent nanobodies to combat escaping mutations through synchronized avidity between
binding epitopes. In particular, picomolar nanobodiesNb12 and Nb30 revealed binding
to a conserved RBD epitope outside of the ACE2-binding motif, which is not accessible to
human antibodies allowing for combat escape mutations at E484 and N501 positions [53].
These studies suggested that nanobody mixtures and rationally engineered bi-paratopic
nanobody constructs could offer a promising alternative to conventional monoclonal antibodies and may be advantageous for controlling a broad range of infectious variants
while also suppressing the emergence of virus escape mutations. Furthermore, bi-paratopic
nanobodies showed significant advantages compared to monoclonal antibodies, single
nanobodies, and nanobody cocktails by effectively leveraging binding avidity and allosteric
cooperativity mechanisms in combating escape mutations. The recent biophysical studies
indicated that avidity-driven mechanisms might underlie functional effects of nanobody
combinations and multivalent nanobody constructs to prevent viral escape making it
possible to rationally engineer desirable levels of binding specificity and generation of
ultra-potent molecules for targeting SARS-CoV-2 S proteins. Avidity-inspired nanobody
therapeutics can leverage the emerging evidence of how binding affinity, avidity, and cooperativity are balanced in a complex thermodynamic mechanism of synchronous binding of
multivalent nanobody constructs [38].
The emergence of variants of concern (VOCs) with the enhanced transmissibility
and infectivity profile including the D614G variant [54–57], B.1.1.7 (alpha) [58–61], B.1.351
(beta) [62,63], B.1.1.28/P.1 (gamma) [64], and B.1.1.427/B.1.429 (epsilon) variants [65,66]
have attracted enormous attention in the scientific community and a considerable variety of the proposed mechanisms explaining functional observations from structural and
biochemical perspectives. The detection of common mutational changes such as D614G,
E484K, N501Y, and K417N that are shared among major circulating variants B.1.1.7, B.1.351,
and B.1.1.28/P.1 indicated that these positions could be particularly critical for modulation
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of the SARS-CoV-2 S protein responses. Biophysical studies of the SARS-CoV-2 S trimers
for these variants revealed structural and functional effects of mutations that can modulate
dynamics and stability of the closed and open forms, increase binding to the human receptor ACE2, and confer immunity escape from vaccines and different classes of monoclonal
antibodies and nanobodies [67–71].
The recent VOC, omicron (B.1.1.529), displaying a large number of mutations in the
S-RBD regions, has further intensified the scientific and public interest and concerns about
the role and mechanisms underlying the emergence of variants [72–76]. The latest structural
and biophysical tour-de-force investigation convincingly demonstrated that OmicronB.1.1.529 mutational diversity could induce a widespread escape from neutralizing antibody
responses [75]. According to this study, mutations S477N, Q498R, and N501Y increase
ACE2 affinity by 37-fold, serving to anchor the RBD to ACE2, while allowing the RBD
region freedom to develop further mutations, including those that reduce ACE2 affinity in
order to evade the neutralizing antibody response [75]. Strikingly, K417N, T478K, G496S,
Y505H, and the triple S371L, S373P, S375F can reduce affinity to ACE2 while driving
immune evasion and providing a final net affinity for ACE2 similar to the original virus.
Structural studies examined several VOCs and demonstrated that Omicron variant RBD
binds to human ACE2 with comparable affinity to that of the original virus [76]. The crystal
and cryo-EM structures of Omicron RBD complexed with human ACE2 identified the role
of key residues for receptor recognition showing that mutations E484A, Q493R, and Q493R
are responsible for immune escape from monoclonal antibodies.
Biophysical studies provided an enormous insight into the mechanisms underlying
differential binding of the S protein variants to the host receptor ACE2 and antibodies.
A series of illuminating biophysical investigations analyzed the biophysical properties
of the SARS-CoV-2 S-glycoprotein binding to ACE2 on model surfaces and on living
cells using force–distance (FD) curve-based atomic force microscopy (FD-curve-based
AFM) [77,78]. By using atomic force microscopy and computer simulations, the kinetic
and thermodynamic parameters of binding between the ACE2 receptors on the model
surface and S-RBD variants (Alpha, Beta, Gamma, and Kappa) were investigated [78].
By providing unprecedented atomistic-level details and significant insight into molecular
binding mechanisms of the SARS-CoV-2 variants, this study observed that the N501Y
and E484Q mutations are particularly important for the greater stability, while the N501Y
mutation is unlikely to significantly affect antibody neutralization [78]. By probing the
interactions using AFM force spectroscopy, it was shown that the RBD mutations in different
variants typically result in the higher stability and affinity of the complex with ACE2,
which can mediate the increased transmissibility [78]. Moreover, integration of biophysical
experiments and molecular simulations support the idea of a stabilized interface through
multiple weaker molecular interactions that cooperatively stabilize the interface between
the RBD and the ACE2 receptor.
Computer simulations and protein modeling also played an important role in shaping
our understanding of the dynamics and function of SARS-CoV-2 glycoproteins [79–82]. Allatom molecular dynamics (MD) simulations of the full-length SARS-CoV-2 S glycoprotein
embedded in the viral membrane, with a complete glycosylation profile, were first reported
by Amaro and colleagues, providing an unprecedented level of details and significant
structural insights about functional S conformations [81,82]. A simplified model of the
SARS-CoV-2 virion integrated data from cryo-EM, x-ray crystallography, and computational predictions to build molecular models of structural SARS-CoV-2 proteins assemble
a complete virion model [83]. Multi-microsecond MD simulations of a 4.1 million atom
system containing a patch of viral membrane with four full-length, fully glycosylated and
palmitoylated S proteins allowed for a complete mapping of generic antibody binding
signatures and characterization of the antibody and vaccine epitopes [84]. MD simulations
and free energy landscape mapping studies of the SARS-CoV-2 S proteins and mutants
detailed conformational changes and diversity of ensembles, further supporting the notion
of enhanced functional and structural plasticity of S proteins [85–91]. Using data analysis
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and protein structure network modeling of MD simulations, residues that exhibit longdistance coupling with the RBD opening, including sites harboring functional mutations
D614G and A570D, which points to the important role of the D614G variant in modulating
allosteric communications in the S protein [87]. The free energy landscapes of the S protein
derived from MD simulations together with nudged elastic pathway optimization mapping
of the RBD opening revealed a specific transient allosteric pocket at the hinge region that is
located near the D614 position influences RBD dynamics [88].
Computational and biophysical kinetics studies of the SARS-CoV-2 S trimer interactions with ACE2 using the recent crystal structures also provided important insights
into the key determinants of the binding affinity and selectivity [92–95]. Our recent studies combined simplified and atomistic MD simulations with coevolutionary analysis and
network modeling to present evidence that the SARS-CoV-2 spike protein function as an
allosterically regulated machine that exploits the plasticity of allosteric hotspots to finetune response to antibody binding [96–105]. These studies showed that examining the
allosteric behavior of the SARS-CoV-2 spike proteins may be useful to uncover functional
mechanisms and rationalize the growing body of diverse experimental data.
Using MD simulations and protein stability analysis, we recently examined binding of
the SARS-CoV-2 RBD with single nanobodies Nb6 and Nb20, VHH E, a pair combination
VHH E+U, a bi-paratopic nanobody VHH VE, and a combination of CC12.3 antibody and
VHH V/W nanobodies [105]. This study characterized the binding energy hotspots in the
SARS-CoV-2 protein and complexes with nanobodies providing a quantitative analysis
of the effects of circulating variants and escaping mutations on binding that is consistent
with a broad range of biochemical experiments. The results suggested that mutational
escape may be controlled through structurally adaptable binding hotspots in the receptoraccessible binding epitope that are dynamically coupled to the stability centers in the
distant binding epitope targeted by VHH U/V/W nanobodies [105]. Using computerbased design of protein–protein interactions, a number of nanobodies were engineered
in silico and selected based on the free energy landscape of protein docking verified by
the recently reported cocrystal structures [106]. Another computational study examined
binding mechanisms of neutralizing nanobodies targeting SARS-CoV-2 S proteins [107].
All-atom MD simulations totaling 27.6 µs in length using the recently solved structures of
the RBD of SARS-CoV-2 S protein in complex with nanobodies H11-H4, H11-D4, and Ty1
revealed interactions between S-RBD and the nanobodies and estimated that the binding
strength of the nanobodies to RBD is similar to that of ACE2 [107].
In the present work, we expanded the analysis of the SARS-CoV-2 S protein binding
with nanobodies by performing a large number of high resolution coarse-grained (CG)
simulations followed by full atomistic reconstruction for the complete S protein trimer
complexes with multivalent nanobodies Nb6, VHH E, and VHH E/VHH V nanobodies. In
addition, we also performed all-atom MD simulations and provided a detailed comparative
analysis of conformational dynamics profiles for the S trimer complexes with the examined
panel of nanobodies. Atomistic dynamics and analysis of collective motions are combined
with a battery of computational tools to examine energetics and allosteric interactions,
including binding free energy scanning, perturbation-response scanning, and network
modeling. Through the synergistic application of these simulation methods, we examine
the atomic-level mechanisms of binding-induced allosteric modulation in the SARS-CoV-2
S trimer complexes with nanobodies. By quantifying energetic and allosteric determinants
of the SARS-CoV-2 S binding with nanobodies, we also analyze the effects of escaping
mutations and the effect of the Omicron variant mutations on nanobody binding. The
results suggest that binding affinity and allosteric signatures of the SARS-CoV-2 complexes
can be determined by a dynamic cross-talk between structurally stable regulatory centers
and conformationally adaptable allosteric hotspots that collectively control resilience to
mutational escape.

complexes can be determined by a dynamic cross-talk between structurally stable regulatory centers and conformationally adaptable allosteric hotspots that collectively control
resilience to mutational escape.
Int. J. Mol. Sci. 2022, 23, 2172

2. Results and Discussion

6 of 29

2.1. Conformational Dynamics and Collective Motions of the SARS-CoV-2 S Trimer Complexes:
Nanobody-Induced Modulation of Flexibility and Escape Mutation Sites as Regulatory Hinges
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A comparative analysis of the conformational flexibility profiles for the S trimer com
plexes with Nb6, VHH E, and VHH E/VHH V nanobodies revealed stabilization of th
interacting regions that was particularly strong in the complex with the VHH E/VHH

Int. J. Mol. Sci. 2022, 23, x FOR PEER REVIEW

Int. J. Mol. Sci. 2022, 23, 2172

9 of 31

8 of 29recongeneral, our results supported the previous studies [109], indicating that atomistic
struction of CG-CABS trajectories could produce adequate protein flexibility profiles that
are consistent with all-atom simulations and, due to a much lower cost, allow for multiple
A comparative
of the conformational
profiles
for the S trimer
independent
runs andanalysis
accumulation
of statisticallyflexibility
significant
averages.
complexes
with
Nb6,
VHH
E,
and
VHH
E/VHH
V
nanobodies
revealed
of
Structural maps of the conformational dynamics profiles for thestabilization
S-RBD complexes
the
interacting
regions
that
was
particularly
strong
in
the
complex
with
the
VHH
E/VHH
with Nb6 (Figure 3A), VHH E (Figure 3B), and VHH VE (Figure 3C) illustrated an appreV nanobody pair (Figure 2A). The RBD core α-helical segments (residues 349–353, 405–410,
ciable mobility of the NTD and RBD residues in the 3-up complexes with VHH E and
and 416–423) showed small thermal fluctuations in all complexes. The stability of the
VHH
E/VHH V nanobodies. The closed conformation of the S trimer complex with Nb6
central β strands (residues 354–363, 389–405, and 423–436) was especially pronounced in
is the
more
rigid complex
(Figure with
3A), Nb6
but nanobody
an appreciable
of mobility
could
be seen MD
in the S1
S trimer
(Figurelevel
2A). Both
CG-CABS
and all-atom
subunit
NTD
and
RBD
regions.
The
results
showed
that
the
open
state
of
the
simulation models reproduced the overall stability of the conserved S-RBD core formed S
bytrimer
bound
to VHH
E nanobody
(Figure
3B) with
all RBDs
in the
up position
are generally
antiparallel
β strands
(β1 to β4 and
β7) (residues
354–358,
376–380,
394–403,
431–438, 507–516)
(Figures
2 and
MD while
simulations
also showed
moderate
fluctuations
of even
more
flexible
in3).
theAtomistic
S1 regions,
structural
rigidityonly
of the
S2 regions
becomes
β5
and
β6)
(residues
451–454
and
492–495)
that
connect
the
mobile
RBM
region
to
the
more pronounced for these states. Accordingly, collective movements of the S1 regions
central core
(Figure
2).S2
The
results
showed
thatmore
Nb6 binding
to the closed
of open
anchored
by the
rigid
core
could
become
pronounced
in the conformation
more dynamic
the S trimer could induce a more significant stabilization of the S-RBD and RBM residues
states, allowing for large rigid body movements of the NTD and RBD regions.

(Figure 2A).

Figure 3. Structural maps of the conformational mobility profiles for the SARS-CoV-2 S protein

Figure
3. Structural
maps
of the conformational
profiles
forthe
theSARS-CoV-2
SARS-CoV-2
S protein
variants
obtained from
CG-CABS
simulations. Themobility
dynamics
maps for
S trimer
in variants
fromNb6
CG-CABS
simulations.
The
dynamics
for the with
SARS-CoV-2
S trimer in the
the obtained
complex with
nanobody,
pdb id 7KKK
(A),
S trimer inmaps
the complex
VHH E nanobody,
complex
with Nb6
nanobody,
idcomplex
7KKK (A),
trimer
in the Vcomplex
with
E nanobody,
pdb id 7KSG
(B), and
S trimer pdb
in the
withSVHH
E/VHH
nanobody,
pdbVHH
id 7B18
(C).
pdb
id
7KSG
(B),
and
S
trimer
in
the
complex
with
VHH
E/VHH
V
nanobody,
pdb
id
7B18
(C). The
The structures are in sphere-based representation rendered using UCSF ChimeraX [108] with the
structures
are
in
sphere-based
representation
rendered
using
UCSF
ChimeraX
[108]
with
the
rigidity-to-flexibility sliding scale colored from blue to red. The positions of sites of circulating rigidity-to-flexibility
scale
colored
from in
blue
to spheres
red. Theand
positions
of sites
of circulating
mutations K417,sliding
E484, and
N501
are shown
large
highlighted
for the
protomers. mutations
The
K417,
E484,
and
N501
are
shown
in
large
spheres
and
highlighted
for
the
protomers.
The structural
structural maps are projected onto the original cryo-EM structures.
maps are projected onto the original cryo-EM structures.
Interestingly, all-atom MD simulations of the SARS-CoV-2 S trimer bound to Nb6
revealed
a more significant
of the RBD
as compared
to thenanobody
conformational
This dynamics
patternmobility
is consistent
withregions
the notion
that single
binding to
profile
obtained
in
the
CG-CABS
simulations
(Figure
2B).
A
greater
level
of
flexibility
the ACE2 binding site can only partly restrict the intrinsic mobility of the RBDwas
regions,
seen in CG-CABS and atomistic MD simulations for the S-RBD regions in the S trimer
allowing for conformational adaptability and potential escape from neutralization. Intercomplexes with VHH E (Figure 2C) and VHH E/VHH V nanobodies (Figure 2D). Hence,
estingly,
the conformational
map
of the open
trimer
complex in
with
the conformational
plasticity ofdynamics
the RBD-up
conformations
canSstill
be maintained
the VHH
E/VHH
V nanobodies
showed
more significant
rigidification
of the entire
S protein, incomplexes
with nanobodies.
In acomparison
with all-atom
MD trajectories,
the CG-CABS
cluding
both S1 and
S2 average
subunits
(Figure
3C). Although
RBDs are
theprevious
up position,
model produced
higher
residue
oscillations,
which isthe
consistent
withinthe
nanobody
two
distinct
can impose
severe
validationbinding
studies ofatthe
CABS
modelepitopes
[109]. Consistently,
bothmore
CG-CABS
andrestrictions
all-atom MDon the
simulations
highlighted
the greater
stability
of the
highly conserved
(residues interRBD
movements
and arguably
allow
for more
effective
inhibitionS2ofsubunit
the RBD-ACE2

actions.

Int. J. Mol. Sci. 2022, 23, 2172

9 of 29

686–1162) as compared to a more adaptable S1 subunit that includes NTD (residues 14–306),
RBD (residues 331–528), CTD1 (residues 528–591), and CTD2 (residues 592–685) (Figure 2).
In particular, all-atom MD simulations of the S trimer complex with VHH E nanobody
showed a more significant difference in the stabilization of the S1 and S2 domains by
displaying very small fluctuations in the S2 regions and larger fluctuations of the S1 regions.
(Figure 2C). Although the VHH E epitope is very similar to that of other nanobodies in this
class, such as Nb6, VHH E binds in a specific orientation in which an extended β-hairpin
conformation protrudes into the RBD binding site (Figure 2B,C). Conformational dynamics
profiles reaffirmed stability of the α-helical segments in the RBD that are located near the
cryptic binding epitope (residues 369–384) targeted by the VHH V nanobody. Importantly,
binding of the VHH V nanobody to the cryptic epitope restricted mobility of the S2 subunit
residues (Figure 2A). Based on these observations, we argue that these residues could
provide a stable anchoring platform at the cryptic epitope for the VHH V nanobody, while
allowing for optimization of binding interactions with the more dynamic RBD binding
epitope (Figure 2).
To highlight similarities and differences in the mobility profiles derived from CG-CABS
and all-atom MD simulations, we performed a simple statistical analysis and computed
averages and standard deviations of the RMSF values. In addition, to compare CG-CABS
and all-atom MD trajectories and establish a correspondence between the dynamics profiles
produced through atomistic reconstruction of CG-CABS trajectories and all-atom MD
simulations, we computed the average Spearman’s correlation coefficient (rs ) between the
respective RMSF profiles. Given the differences between these simulation models, the
correlation analysis confirmed a similar pattern of protein flexibility, yielding statistically
significant correlation rs = 0.68 for the S trimer complexes with Nb6, rs = 0.723 for the
S trimer complexes with VHH E, and only slightly lower rs = 0.624 for the complex with
VHH E/VHH V nanobody. These results are similar to the outcome of the large-scale
validation study that yielded the average Spearman’s correlation coefficient of rs ~ 0.7
between the RMSFs of the CG-CABS and atomistic simulations for the diverse protein
set [109]. Interestingly, this study also showed that correlations among MD trajectories
obtained from different all-atom force fields could vary in a similar range (0.75–0.82) [109].
The observed similarities of the conformational dynamics profiles suggested that CGCABS simulations could provide a fairly accurate and affordable simulation approach
for quantifying flexibility of the SARS-CoV-2 S complexes with the panel of nanobodies.
In general, our results supported the previous studies [109], indicating that atomistic
reconstruction of CG-CABS trajectories could produce adequate protein flexibility profiles
that are consistent with all-atom simulations and, due to a much lower cost, allow for
multiple independent runs and accumulation of statistically significant averages.
Structural maps of the conformational dynamics profiles for the S-RBD complexes with
Nb6 (Figure 3A), VHH E (Figure 3B), and VHH VE (Figure 3C) illustrated an appreciable
mobility of the NTD and RBD residues in the 3-up complexes with VHH E and VHH
E/VHH V nanobodies. The closed conformation of the S trimer complex with Nb6 is more
rigid (Figure 3A), but an appreciable level of mobility could be seen in the S1 subunit NTD
and RBD regions. The results showed that the open state of the S trimer bound to VHH E
nanobody (Figure 3B) with all RBDs in the up position are generally more flexible in the
S1 regions, while structural rigidity of the S2 regions becomes even more pronounced for
these states. Accordingly, collective movements of the S1 regions anchored by the rigid S2
core could become more pronounced in the more dynamic open states, allowing for large
rigid body movements of the NTD and RBD regions.
This dynamics pattern is consistent with the notion that single nanobody binding to the
ACE2 binding site can only partly restrict the intrinsic mobility of the RBD regions, allowing
for conformational adaptability and potential escape from neutralization. Interestingly,
the conformational dynamics map of the open S trimer complex with VHH E/VHH V
nanobodies showed a more significant rigidification of the entire S protein, including
both S1 and S2 subunits (Figure 3C). Although the RBDs are in the up position, nanobody
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binding at two distinct epitopes can impose more severe restrictions on the RBD movements
and arguably allow for more effective inhibition of the RBD-ACE2 interactions.
We characterized collective motions for the SARS-CoV-2 S-RBD complexes averaged
over low-frequency modes using principal component analysis (PCA) of the trajectories
(Figure 4). The local minima along these profiles are typically aligned with the hinge centers,
while the maxima correspond to the moving regions undergoing concerted movements.
The low-frequency ‘soft modes’ are often functionally important as mutations or binding
can exploit and modulate protein movements along the pre-existing slow modes to induce
allosteric transformations. The overall shape of the essential profiles in the SARS-CoV2 S trimer complex with Nb6 showed suppressed movements of RBDs that are in the
down position (Figure 4A,B). On the other hand, the profile displayed larger functional
displacements of the NTD regions. The immobilized hinge positions of the S trimer
corresponded to positions F318, L387, F429. The slow mode profile of the S trimer complex
with Nb6 showed the reduced RBD mobility, but the tip of the RBM loop (residues 473–483)
remained mobile in functional dynamics. The sites of typical nanobody-escaping mutations
(G447, Y449, L452, F490, Q493, Y508) correspond to the low mobility RBD regions in
slow modes of the S trimer (Figure 4A,B). Although the RBD region harboring E484/F486
positions undergoes some functional motions in the slow modes, these movements are
relatively moderate as compared to the NTD fluctuations that dominate collective dynamics.
Nb6 binding could be severely compromised by the E484K mutation, while other sites
of nanobody-escaping mutations are likely to be suppressed by the nanobody [43]. This
may be partly explained based on the functional dynamics profiles in which most of these
positions are immobilized by Nb6 binding, whereby the absence of functional motions
could restrict the mutational escape potential. The fact that only the tip of the RBM region
and E484/F486 remain more prone to changes could allow for E484K mutation to escape
Nb6 binding and adopt a conformation evading efficient nanobody interactions. The slow
mode profile of the S trimer complex with VHH E nanobodies in which all RBDs are in
the up position showed a clearly different pattern (Figure 4C,D). In this case, the RBDs
correspond to moving regions. The rigid hinge centers are located at conserved F318 and
V534, F592 residues. Several local hinge positions are aligned with I358, A363, Y365, L387
in the RBD core due to constraints imposed by RBD interactions with NTD of the adjacent
protomer. The local maxima of the slow mode profile corresponded to V350, V369, S371,
F377, K378, G447, Y449, L452, and 476–492 cluster (Figure 4C,D). Some of these functionally
mobile residues are not involved in the interactions with VHH E nanobody (V350, V369,
S371, F377, K378) and allow for conformational rearrangements of these flexible RBD
regions. Instructively, nanobody binding can be partly escaped by mutations Y369H, S371P,
F377L, and K378Q/N, even though these modifications are not currently circulating.
Hence, the sites of escaping mutations are aligned with the functionally moving RBD
regions, which may experience functional displacements and affect the RBD conformation,
thereby reducing the efficiency of VHH E binding. The largest peaks in the slow mode
profile are aligned with K417, F456, and RBM residues E484/F486 (Figure 4C,D). Movements of these positions may affect the fidelity of nanobody binding, and mutations in
these positions, particularly E484K, can escape the nanobody effect owing to the inherent
functional plasticity in this region. This may contribute to a certain level of vulnerability
shown by nanobodies Nb6 and VHH E targeting the ACE2-binding site to mutations in
K417 and E484 residues. Structural maps of the slow mode profiles for the S complex with
VHH E (Figure 4D) illustrate the greater mobility of the RBM residues and plasticity of the
binding epitope. A similar picture was observed for the collective dynamics analysis of the
S complex with VHH VE nanobody (Figure 4E,F). Our analysis indicated that the VHH
VE nanobody could modulate conformational dynamics without dramatically altering
collective motions but rather fine-tune dynamic changes at the binding site. These findings
are consistent with the experimental evidence showing that VHH E and VHH V nanobodies
that target two independent epitopes can activate the SARS-CoV-2 fusion machinery [49].
Although VHH VE binding can curtail flexibility of the S1 regions and impose structural
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constraints in the binding sites, functional RBD motions are still characteristic of the S
complexes may contribute to mutational adaptation as sequences containing mutations
in both interfaces were detected in the presence of VHHs E and V [49]. The results11may
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explain why flexible RBD sites F486 and F490 are often featured as common sites of escape
mutants that dominate the VHH E interface [49].
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the S-RBD complex [105]. In the S trimer complex, however, a single Nb6 molecule is
positioned at the interface between two adjacent RBDs (Figure 1) [43]. The experimental
studies suggested that a single Nb6 can stabilize two adjacent RBDs in the down state and
prime the binding site for a second and third Nb6 molecule to stabilize the 3 RBD-down
S conformation [43]. Mutational scanning of the S trimer revealed the binding energy
hotspots in each protomer that are distributed through two interfaces, each interacting
with a different Nb6 molecule (Figure 5). One of the interfaces corresponded to the cryptic
binding RBD site where one Nb6 molecule interacts with N343, V367, S371, S373, V374,
W436 hotspots (Figure 5). Our previous studies showed that highly conserved sites F374
and W436 are important coevolutionary centers that are often implicated in interactions
with neutralizing antibodies [98,99]. The other Nb6 molecule binds to the ACE2-binding site
on the RBD where the key binding energy hotspots corresponded to hydrophobic residues
Y449, L453, L455, F456, Y489, F490, G496, and Y505 (Figure 5). A number of these positions
are also binding affinity hotspots for ACE2, as evident from deep mutagenesis scanning of
SARS-CoV-2 interactions with the ACE2 host receptor [117–120]. The interaction pattern
and similarity in the binding energy hotspots with ACE2 supported the notion of structural
Int. J. Mol. Sci. 2022, 23, x FOR PEER REVIEW
13 of 31
mimicry that may be efficiently exploited by Nb6 nanobody to competitively inhibit the
ACE binding region.
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was experimentally determined that Nb6 binding could be severely impeded by E484K
mutation [49]. We specifically examined the effect of mutations present in the S-B.1.1.7
variant (N501Y) and S-B1.351 variant (K417N, E484K, N501Y on Nb6 and VHH E binding.
It appeared that K417N and N501Y mutations only moderately affected nanobody binding.
Somewhat more moderate but still noticeable destabilization changes can be induced in
the S trimer complexes with VHH E nanobody upon mutations of L452 and E484 sites
(Figure 5). Hence, these nanobody-escaping mutations center at highly antigenic sites. The
moderate stability for sites of escaping mutations is consistent with the notion that the
virus tends to target positions where mutations would not appreciably perturb the RBD
folding stability that is a prerequisite for proper activity of spike protein and binding with
the host receptor. By targeting dynamic and structurally adaptable hotspots such as E484,
F486, and F490 that are relatively tolerant to mutational changes, the virus tends to exploit
conformational plasticity in these regions in eliciting specific escape patterns that would
impair nanobody binding.
For the S trimer complex with VHH VE nanobody, the binding footprint revealed
several clusters of binding energy hotspots (Figure 6) targeting two different epitopes.
Int. J. Mol. Sci. 2022, 23, x FOR PEER REVIEW
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the binding epitope sites. The squares on the heatmap are colored using a 3-colored scale—from blue
to yellow, with yellow indicating the largest destabilization effect. Structural map of the binding
epitopes and binding energy hotspots for VHH VE. The S-RBD is shown in green surface. The epitope
residues are in red, and the binding energy hotspots are shown in blue surface. The computed
standard errors of the mean for the binding free energy changes are based on selected samples
from atomistic trajectory reconstructed from CG-CABS simulations (1000 samples) and are within
0.15–0.23 kcal/mol.

Consistent with our earlier studies [105], mutational scanning and energetic cartography analysis suggested that VHH E/VHH V can use binding of VHH V at the cryptic
binding site to form a structurally stable anchoring platform that allows for modulation of
functional movements of VHH E and provides allosteric control over structural changes in
the RBM epitope. Due to synergistic avidity effects, binding of the VHH E arm at the RBM
epitope may then lower the entropic penalty and allow for local structural accommodations
to compensate for the loss of binding interactions. This may underlie a mechanism by
which multivalent nanobodies can leverage long-range couplings to synergistically inhibit
distinct binding epitopes and suppress mutational escape.
We also examined the effect of Omicron mutations in the RBD (G339D, S371L, S373P,
S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H)
on binding of Nb6, VHH E, and VHH E/VHH V nanobodies (Figure 7). Importantly, some
of the Omicron mutations could significantly affect Nb6 binding, particularly G446S, E484A,
G496S, and Y505H modifications (Figure 7A,B). The results confirmed the important role of
E484 and N501 positions for protein stability and binding affinity, which is consistent with
the atomic force spectroscopy studies showing the impact of mutations in these sites on
binding energetics with the host receptor [78]. Recent studies also showed that Omicron
mutations S477N, Q498R, and N501Y could increase ACE2 affinity anchoring the RBD
to ACE2 [75]. These mutations have a moderate destabilization effect on Nb6 nanobody
binding, thus potentially reducing the neutralization capacity. Moreover, it was proposed
that K417N, T478K, G496S, Y505H, and the mutations at the cryptic epitope S371L, S373P,
S375F can reduce affinity to ACE2 while driving immune evasion [76]. According to our
data, most of these mutations, particularly G496S, Y505H, S371L, and S373P, could indeed
adversely affect protein stability and binding affinity with Nb6 nanobody (Figure 7A,B).
This suggests that the Omicron variant could escape the neutralization by Nb6 and this class
of nanobodies with a significant overlap with the ACE2-binding site and binding epitope
that includes most of the mutational sites. For VHH E binding, the large binding affinity
loss resulted from E484A, Q493R, G496S, and N501Y mutations (Figure 7C,D). Importantly,
these mutations are among common resistant mutations that evade many individual
nanobodies [46]. Moreover, structural studies showed that Omicron mutations E484A,
Q493R, and Q498R are largely responsible for immune escape from monoclonal antibodies.
According to the recent study, the Omicron variant can escape the neutralization of many
monoclonal antibodies, where the K417N, Q493R, and E484A Omicron mutations affect
the recognition of class 1 and 2 antibodies targeting the ACE2 binding epitope [121]. Our
results indicated that both Nb6 and VHH E could be sensitive to these Omicron mutations
that appeared to reduce binding affinity and therefore have the potential to compromise
neutralization of this class of nanobodies. These observations are consistent with the
most recent study of 17 nanobodies tested against SARS-CoV-2 variants showing that
efficient neutralization of the Omicron variant may be observed for synergistic nanobodies
targeting multiple unique binding epitopes and exploiting conserved and cryptic epitope
accessible only in the receptor-binding domain up conformation [122]. The important
revelation of this analysis is appreciably smaller binding free energy changes induced
by RBD-Omicron mutations in the SARS-CoV-2 S protein complex with VHH E/VHH
V nanobodies (Figure 7E,F). In this case, a noticeable reduction of binding affinity was
observed only for E484A, Q493R, and G496S mutations. These mutations emerged as
a consistent hotspot among Omicron RBD variants that affected binding affinity with
all examined nanobodies (Figure 7). It was recently shown that these mutations in the
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Omicron spike are compatible with the usage of diverse ACE2 orthologues for entry and
could amplify the ability of the Omicron variant to infect animal species [123]. Interestingly
mutations in G446, S477, T478, E484, F486 are associated with resistance to more than
one monoclonal antibody, and substitutions at E484 can confer a broad resistance [124].
Moreover, mutations at the E484 position (E484A, E484G, E484D, and E484K) confer partial
resistance to the convalescent plasma, showing that E484 is also one of the dominant
epitopes of spike protein [123,124]. The experimental studies also showed that E484 is the
“Achilles’s heel” for several important classes of antibodies and nanobodies [44,45,125].
The mutational scanning analysis supported the notion that E484A mutation can have a
significant detrimental effect on nanobody binding and result in Omicron-induced escape
from nanobody neutralization.
Interestingly, our results also showed that VHH E/VHH V nanobody binding could
be potentially less sensitive to Q498R, N501Y, and Y505H mutations (Figure 7E,F) as
compared to binding of a single nanobody VHH E (Figure 7C,D). Accordingly, synergistic
combinations of nanobodies targeting distinct binding epitopes may be more resistant to
mutational escape and become less sensitive to the Omicron mutations. This is consistent
with recent experiments on nanobodies and nanobody combinations, showing a remarkable
ability of synergistic and especially multivalent nanobodies to combat escaping mutations
through avidity-driven mechanisms between binding epitopes [53]. Moreover, the latest
report of the design of a bi-paratopic nanobody, Nb1-Nb2, with high affinity and superwide neutralization breadth against multiple variants [126]. Deep-mutational scanning
experiments demonstrated that bi-paratopic Nb1-Nb2 is resistant to mutational escape
against more than 60 RBD mutations and retains tight affinity and strong neutralizing
activity against the Omicron virus. These illuminating experimental studies provide some
support to our findings, suggesting that synergistic combinations targeting nonoverlapping
epitopes on the RBD could be more effective in combating Omicron mutations than single
nanobodies. It is worth noting that a broad spectrum mutational resistance of the discovered
Int. J. Mol. Sci. 2022, 23, x FOR PEER REVIEW
16 of 31
tetravalent bi-paratopic nanobody Nb1-Nb2 is significantly enhanced by exploiting unique
and partially separated binding epitopes that emerged as a result of the bivalent fusion of
Nb1 and Nb2 [126].
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on S trimer binding with Nb6 (A), VHH E (C), and VHH E/VHH V nanobody (E). The computed
standard errors of the mean for the binding free energy changes are based on number of selected
samples from atomically reconstructed CG-CABS trajectories (~1000 samples) and are generally
within 0.07–0.18 kcal/mol. The error bars are shown in whisker error bar style. (B) Structural view
of the S-RBD (in red ribbons) bound to Nb6 nanobody (in pink ribbons). (D) Structural view of the
S-RBD (in red ribbons) bound to VHH E nanobody (in pink ribbons). (F) Structural view of the S-RBD
(in red ribbons) bound to VHH E (in pink ribbons) and VHH V (in magenta ribbons). The positions
of Omicron-RBD mutations are shown in spheres and annotated.

2.3. Perturbation Response Scanning of the SARS-CoV-2 S Complexes with Nanobodies Highlights
Allosteric Role of Escaping Mutation Sites
Using the perturbation-response scanning (PRS) method [127–134], we quantified
the allosteric effect of each residue in the SARS-CoV-2 complexes with a panel of studied
nanobodies. The effector profiles estimate the propensities of a given residue to influence
allosteric dynamic changes in other residues and are applied to identify regulatory hotspots
of allosteric interactions as the local maxima along the profile. We propose that escaping
variations could preferentially target structurally adaptable regulatory centers of collective
movements and allosteric communications in the SARS-CoV-2 S complexes. To validate
this hypothesis, we probed the allosteric effector potential of the S residues in complexes
with studied nanobodies.
The PRS effector profile for the S-RBD residues in the complex with Nb6 showed a
significant overlap with the complex with ACE2 (Figure 8A,B). In the complex with Nb6,
several effector peaks corresponding to structurally stable RBD regions (residues 348–352,
400–406) as well as S371, S373, V374, W436 positions from the cryptic site involved in
interactions with Nb6 nanobody. The largest effector values corresponded to RBD residues
Q493, G496, L452, and Y508 (Figure 8A). Notably, a number of local maxima were also
aligned with the sites of escaping mutations, particularly Y449, L452, L453, F490, L492,
Q493, and Y508 positions (Figure 8A). Hence, these residues can exhibit a strong allosteric
potential in the complex and function as effector hotspots of allosteric signal transmission
(Figure 8A,B). In contrast, sites of circulating mutations K417, E484, and N501 belong to
local minima of the profile, which implies these residues are flexible sensors or transmitters
of allosteric changes. This analysis also suggested that sites of escaping and circulating
mutations may play a role in allosteric couplings of stable and flexible RBD regions that
control signal propagation in the spike protein. While modifications of K417 and N501
residues appeared to trigger moderate changes in the binding affinity, the perturbations
inflicted on these sites would have a significant effect on allosteric signaling in the complex.
The results indicated that functional RBD sites might play complimentary roles in allosteric
communications in the S complexes. While positions L452, Q493, G496 correspond to
local maxima of the PRS profile and can assume the role of the effector regulatory points
that could dispatch allosteric signals through RBD regions, other functional sites such
as more flexible E484, F486, and Y501 are aligned with local minima and may act as
receivers/transmitters of the allosteric signal involved in functional RBD movements.
Structural mapping of allosteric effector hotspots for the S trimer complex with Nb6
nanobody revealed two clusters of residues: one cluster is in the S-RBD core region near the
cryptic binding epitope, and the second cluster is near the RBM epitope (Figure 8B). These
clusters form a network of functional centers that connects two binding epitopes and allow
for signal transmission in the complex. It is particularly interesting given that Nb6 binds
only to one of these binding epitopes. This suggests that allosteric effector centers in the
RBD are allocated near the binding epitopes and are intrinsic to the S protein architecture.
In this context, the pre-existing network of allosteric effector centers can be activated and
modulated by nanobody binding that can exploit specific effector hotspots to allosterically
propagate the binding signal to other epitopes and functional regions. We also found that
the E484 site may be a critical effector hotspot for Nb6 binding. Allosteric versatility of this
functional site could make it vulnerable to mutations which may alter collective dynamics
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and potentially be a driver of resistance to nanobodies. Indeed, mutations in the epitope

centered on the E484 position (F486, F490) were shown to strongly affect neutralization for
different classes of nanobodies.
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case, the dominant, sharp peak corresponded to a cluster of residues (S371, S373, V374, F377,
K378) from the cryptic site that interacts with VHH V. Smaller local peaks are associated
with the RBD positions from the ACE2-binding site, primarily Q493, Q498, andY508
(Figure 8E). As a result, VHH VE binding could shift the distribution towards allosteric
sites from the cryptic binding site that regulate signal propagation in the S complex, while
functional residues from the RBM binding site may serve as sensors of the binding signal.
The diminished dependency of allosteric signaling induced by VHH VE nanobody on the
common sites of escaping mutations may be related to the effects of multimeric nanobody
combinations that allow for a reduction in susceptibility to escape mutations. This suggests
a plausible mechanism by which bi-paratopic nanobodies can leverage dynamic couplings
to synergistically inhibit distinct binding epitopes and suppress mutational escape. To
summarize, perturbation-based scanning results revealed the allosteric role of functional
sites targeted by escaping mutations and the Omicron variant. Collectively, our findings
suggested that SARS-CoV-2 S protein may exploit the plasticity of specific allosteric hotspots
to generate escape mutants that alter response to binding without compromising activity.
2.4. Network Centrality Analysis of Global Mediating Centers in the SARS-CoV-2 Complexes with
Nanobodies Identifies Clusters of Allosteric Hotspots Targeted by Escaping Mutations
Network-centric models of protein structure and dynamics can allow for a more
quantitative analysis of allosteric changes, identification of regulatory control centers,
and mapping of allosteric communication pathways. The residue interaction networks
in the SARS-CoV-2 spike trimer structures were built using a graph-based representation of protein structures [135,136] in which residue nodes are interconnected through
dynamic correlations [137]. By employing network centrality calculations for the equilibrium ensembles of the SARS-CoV-2 S trimer complexes with nanobodies [138,139], we
computed ensemble-averaged distributions of the short path residue centrality (Figure 9).
This network metric was used to identify mediating centers of allosteric interactions in the
SARS-CoV-2 complexes. In the context of the network-based centrality analysis, residues
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mediating a significant number of shortest pathways between all possible residue pairs in
the system are identified by higher betweenness centrality.

Figure 9.
9. Network
Network centrality
S trimer
complexes
with
nanobodies.
(A) The
Figure
centralityanalysis
analysisofofthe
theSARS-CoV-2
SARS-CoV-2
S trimer
complexes
with
nanobodies.
(A)
ensemble-averaged
shortshort
path betweenness
centrality
for thefor
SARS-CoV-2
S trimerSin
the complex
with
The
ensemble-averaged
path betweenness
centrality
the SARS-CoV-2
trimer
in the complex
Nb6 nanobody,
pdb
id S7KKK
S trimer
in the
VHHpdb
E nanobody,
pdband
id
Nb6 with
nanobody,
pdb id 7KKK
(A),
trimer(A),
in the
complex
withcomplex
VHH E with
nanobody,
id 7KSG (C),
7KSG (C), and S trimer in the complex with VHH E/VHH V nanobody, pdb id 7B18 (E). The residuebased profiles are shown for the S trimers are shown in maroon-colored filled bars. The sites of
escaping mutations for nanobody binding are highlighted in blue-colored filled diamonds. (B) The
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S trimer in the complex with VHH E/VHH V nanobody, pdb id 7B18 (E). The residue-based profiles
are shown for the S trimers are shown in maroon-colored filled bars. The sites of escaping mutations
for nanobody binding are highlighted in blue-colored filled diamonds. (B) The structure of the
SARS-CoV-2 S trimer in the complex with Nb6 nanobody. The S trimer is shown in full spheres with
protomers A, B, C colored in light green, red, and blue, respectively. Nb6 nanobodies are shown in
yellow spheres. The structural maps are projected onto the original cryo-EM structures. The rendering
of SARS-CoV-2 S structures was done using the visualization program UCSF ChimeraX [108]. The
sites of escaping mutations are highlighted in large spheres colored according to the respective
protomer. A closeup of the S-RBD bound to Nb6. S-RBD is in orange ribbons, and Nb6 is in
magenta ribbons. The sites of escaping mutations are shown in orange spheres and correspond to
the highlighted positions in the centrality profile. (D) The structure of the SARS-CoV-2 S trimer in
the complex with VHH E nanobody. VHH E is in yellow spheres, and sites of escaping mutations
are shown in spheres. A closeup of the S-RBD bound to VHH E with sites of escaping mutations in
orange spheres. The annotations are the same as in panel B. (F) The structure of the SARS-CoV-2 S
trimer in the complex with VHH E/VHH V nanobody. VHH E is in yellow spheres and VHH V is in
orange spheres. A closeup of the S-RBD bound to VHH E/VHH V with sites of escaping mutations
in orange spheres. VHH E is in magenta ribbons, and VHH V is in red ribbons.

The network centrality profiles revealed several characteristic cluster peaks that are
shared among complexes (Figure 9). However, nanobody binding can modulate this
distribution and change the relative contribution of mediating centers. In the S trimer
complexes with N6 and VHH E nanobodies that target the ACE2-binding sites, we observed
the largest peak localized in the cluster of F490, L492, Q493, G496, Q498, and Y508 positions
residues (Figure 9A,B). The second peak is aligned with Y449, L452, L453, and L455 RBD
positions. In network terms, this implies that allosteric signaling in the S complexes with
Nb6 and VHH E can be mediated by these sites that serve as central communication hubs.
As a result, mutations in these positions and loss of interactions can affect not only the local
structural environment of the mutated sites but also impact the global network organization
of the system. Strikingly, a significant number of these mediating centers corresponded
to residues involved in the Omicron variant. Hence, multiple Omicron RBD mutations
(such as Q493R, G496S, Q498R, N501Y, Y505H) may have a measurable effect on allosteric
couplings in the complexes with Nb6 and VHH E nanobodies, which would likely render
some level of resistance to nanobody-induced neutralization.
In contrast, in the S complex with bi-paratopic VHH VE nanobody, a partial redistribution of the network centrality distribution was detected, pointing to the reduced peaks
in the RBD residues from the ACE2-binding site, while showing a moderate centrality for
S-RBD core residues from the cryptic site (S371, F374, S375, F377, C379, Y380). The observed
modulation of high centrality peaks and broadening of the distribution showed that many
residues feature a moderate level of centrality. As a result, VHH VE nanobody binding
can induce long-range couplings between the cryptic binding epitope and ACE2-binding
site through a broader ensemble of communication paths that is less dependent on specific
mediating centers and therefore may be less sensitive to mutational perturbations of functional residues. This suggests a plausible mechanism by which bi-paratopic nanobodies
can leverage dynamic couplings to synergistically inhibit distinct binding epitopes and
suppress mutational escape.
3. Materials and Methods
3.1. Structure Preparation and Analysis
All structures were obtained from the Protein Data Bank [140,141]. During the structure preparation stage, protein residues in the crystal structures were inspected for missing
residues and protons. Hydrogen atoms and missing residues were initially added and
assigned according to the WHATIF program web interface [142,143]. The structures were
further pre-processed through the Protein Preparation Wizard (Schrödinger, LLC, New
York City, NY, USA) and included the check of bond order, assignment, and adjustment of
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ionization states, formation of disulfide bonds, removal of crystallographic water molecules
and co-factors, capping of the termini, assignment of partial charges, and addition of
possible missing atoms and side chains that were not assigned in the initial processing
with the WHATIF program. The missing loops in the studied cryo-EM structures of the
SARS-CoV-2 S protein were reconstructed and optimized using template-based loop prediction approaches ModLoop [144], ArchPRED server [145] and further confirmed by FALC
(Fragment Assembly and Loop Closure) program [146]. The side-chain rotamers were
refined and optimized by the SCWRL4 tool [147]. The conformational ensembles were
also subjected to all-atom reconstruction using the PULCHRA method [148] and CG2AA
tool [149] to produce atomistic models of simulation trajectories. The protein structures
were then optimized using atomic-level energy minimization with composite physics and
knowledge-based force fields as implemented in the 3Drefine method [150]. The atomistic structures from simulation trajectories were further elaborated by adding N-acetyl
glycosamine (NAG) glycan residues and optimized.
3.2. Coarse-Grained Simulations
Coarse-grained (CG) models are computationally effective approaches for simulations
of large systems over long timescales. We employed a CABS-flex approach that efficiently
combines a high-resolution coarse-grained model and efficient search protocol capable
of accurately reproducing all-atom MD simulation trajectories and dynamic profiles of
large biomolecules on a long time scale [151–156]. In this high-resolution model, the
amino acid residues are represented by Cα, Cβ, the center of mass of side chains and
another pseudoatom placed in the center of the Cα-Cα pseudo-bond. In this model,
the amino acid residues are represented by Cα, Cβ, the center of mass of side chains
and the center of the Cα-Cα pseudo-bond. The CABS-flex approach, implemented as a
Python 2.7 object-oriented standalone package [154,155], was used in this study to allow for
robust conformational sampling proven to accurately recapitulate all-atom MD simulation
trajectories of proteins on a long time scale. Conformational sampling in the CABS-flex
approach was conducted with the aid of Monte Carlo replica-exchange dynamics and
involves local moves of individual amino acids in the protein structure and global moves
of small fragments [151–153]. The default settings were used in which soft native-like
restraints are imposed only on pairs of residues fulfilling the following conditions: the
distance between their Cα atoms was smaller than 8 Å, and both residues belong to the
same secondary structure elements. The CABS-flex default distance restraints moderately
penalize the position of restrained residues if their distance differed from the distance in
the original cryo-EM structure becomes more than 1 Å. In these settings, loop regions are
fully unrestrained. A total of 100 independent CG-CABS simulations were performed
for each of the studied systems. In each simulation, the total number of cycles was set to
10,000, and the number of cycles between trajectory frames was 100. MODELLER-based
reconstruction of simulation trajectories to all-atom representation provided by the CABSflex package was employed to produce atomistic models of the equilibrium ensembles for
studied systems [121].
3.3. Molecular Dynamics Simulations
All-atom MD simulations were performed for an N, P, T ensemble in explicit solvent using NAMD 2.13 package [157] with CHARMM36 force field [158]. Long-range
non-bonded van der Waals interactions were computed using an atom-based cutoff of
12 Å with switching van der Waals potential beginning at 10 Å. Long-range electrostatic
interactions were calculated using the particle mesh Ewald method [159] with a real space
cut-off of 1.0 nm and a fourth-order (cubic) interpolation. SHAKE method was used to
constrain all bonds associated with hydrogen atoms. Simulations were run using a leapfrog integrator with a 2 fs integration time step. Energy minimization after addition of
solvent and ions was carried out using the steepest descent method for 100,000 steps. All
atoms of the complex were first restrained at their crystal structure positions with a force
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constant of 10 Kcal mol−1 Å−2 . Equilibration was done in steps by gradually increasing the
system temperature in steps of 20 K starting from 10 K until 310 K, and at each step, 1ns
equilibration was done, keeping a restraint of 10 Kcal mol-1 Å-2 on the protein Cα atoms.
After the restraints on the protein atoms were removed, the system was equilibrated for
additional 10 ns. An NPT production simulation was run on the equilibrated structures
for 500 ns, keeping the temperature at 310 K and constant pressure (1 atm). In simulations,
the Nose–Hoover thermostat [160] and isotropic Martyna–Tobias–Klein barostat [161] were
used to maintain the temperature at 310 K and pressure at 1 atm, respectively. Principal
component analysis (PCA) of MD trajectories was carried out based on the set of backbone
heavy atoms using the CARMA package [162].
3.4. Mutational Scanning and Sensitivity Analysis
We conducted mutational scanning analysis of the binding epitope residues for the
SARS-CoV-2 S protein complexes. Each binding epitope residue was systematically mutated using all possible substitutions, and corresponding protein stability changes were
computed. The BeAtMuSiC approach [110–112] was employed, which is based on statistical potentials describing the pairwise inter-residue distances, backbone torsion angles,
and solvent accessibilities, and considers the effect of the mutation on the strength of
the interactions at the interface and on the overall stability of the complex. The binding
free energy of protein-protein complex can be expressed as seen in Equation (1) by the
difference in the folding free energy of the complex and folding free energies of the two
protein binding partners:
∆Gbind = G com − G A − G B
(1)
The change of the binding energy due to a mutation was calculated then as the
following Equation (2):
mut
wt
∆∆Gbind = ∆Gbind
− ∆Gbind
(2)
We leveraged rapid calculations based on statistical potentials to compute the ensembleaveraged binding free energy changes using equilibrium samples from simulation trajectories. The binding free energy changes were computed by averaging the results over
1000 equilibrium samples for each of the studied systems.
3.5. Perturbation Response Scanning
The Perturbation Response Scanning (PRS) approach [127–134] follows the protocol
originally proposed by Bashar and colleagues [129,130] and was described in detail in
our previous studies [133]. In brief, through monitoring the response to forces on the
protein residues, the PRS approach can quantify allosteric couplings and determine the
protein response in functional movements. In this approach, it 3N × 3N Hessian matrix H
whose elements represent second derivatives of the potential at the local minimum connect
the perturbation forces to the residue displacements. The 3N-dimensional vector ∆R of
node displacements in response to 3N-dimensional perturbation force follows Hooke’s law
F = H ∗ ∆R. A perturbation force is applied to one residue at a time, and the response
of the protein system is measured by the displacement vector ∆R(i ) = H −1 F (i) that is
then translated into N × N PRS matrix. The second derivatives matrix H is obtained
from simulation trajectories for each protein structure, with residues represented by Cα
atoms and the deviation of each residue from an average structure was calculated by
∆R j (t) = R j (t) − R j (t) , and corresponding covariance matrix C was then calculated
by ∆R∆R T . We sequentially perturbed each residue in the SARS-CoV-2 spike structures
by applying a total of 250 random forces to each residue to mimic a sphere of randomly
selected directions. The displacement changes, ∆Ri is a 3N-dimensional vector describing
the linear response of the protein and deformation of all the residues. Using the residue
displacements upon multipleexternal force
perturbations, we compute the magnitude of

the response of residue k as

(i ) 2

k∆Rk k

averaged over multiple perturbation forces F(i) ,

Int. J. Mol. Sci. 2022, 23, 2172

22 of 29

yielding the ikth element of the N × N PRS matrix. The average effect of the perturbed
effector site i on all other residues isDcomputed
by averaging over all sensors (receivers)
2 E
i
residues j and can be expressed as ∆R
e f f ector . The effector profile determines the
global influence of a given residue node on the perturbations in other protein residues and
can be used as proxy for detecting allosteric regulatory hotspots in the interaction networks.
In turn, the jth column of the PRS matrix describes the sensitivity profile of sensor
residue
j
D
2 E
in response to perturbations of all residues and its average is denoted as ∆Ri
sensor .
The sensor profile measures the ability of residue j to serve as a receiver of dynamic changes
in the system.
4. Conclusions
In this study, we performed a comprehensive computational analysis of the SARSCoV-2 S trimer complexes with Nb6, VHH E, and VHH E/VHH V nanobodies. We
combined CG-CABS and all-atom MD simulations with binding free energy scanning,
perturbation-response scanning, and network centrality analysis to examine mechanisms
of nanobody-induced allosteric modulation and cooperativity in the SARS-CoV-2 S trimer
complexes with nanobodies. By quantifying energetic and allosteric determinants of the
SARS-CoV-2 S binding with nanobodies, we also examined nanobody-induced modulation
of escaping mutations and the effect of the Omicron variant on nanobody binding. The
mutational scanning analysis supported the notion that E484A mutation can have a significant detrimental effect on nanobody binding and result in Omicron-induced escape from
nanobody neutralization. The results suggested that by targeting structurally adaptable
hotspots such as E484, F486, and F490 that are relatively tolerant to mutational changes,
the virus tends to exploit conformational plasticity in these regions in eliciting specific
escape from nanobody binding. Using PRS analysis, we found that escaping mutational
variants could preferentially target structurally adaptable regulatory centers of collective
movements and allosteric communications in the SARS-CoV-2 S complexes. We suggested
that reduced dependency of allosteric signaling induced by VHH VE nanobody on the
common sites of escaping mutations may be related to the effects of multimeric nanobody
combinations that allow for reduction of susceptibility to escape mutations. Our findings
showed that SARS-CoV-2 S protein might exploit the plasticity of specific allosteric hotspots
to generate escape mutants that alter response to binding without compromising activity.
The network analysis supported these findings, showing that VHH V/VHH E nanobody
binding can induce long-range couplings between the cryptic binding epitope and ACE2binding site through a broader ensemble of communication paths that is less dependent on
specific mediating centers and therefore may be less sensitive to mutational perturbations
of functional residues. The results suggest that binding affinity and long-range communications of the SARS-CoV-2 complexes with nanobodies can be determined by structurally
stable regulatory centers and conformationally adaptable hotspots that are allosterically
coupled and collectively control resilience to mutational escape.
Funding: This research was supported by the Kay Family Foundation Grant No. A20-0032.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Data is fully contained within the article. The data presented in this
study are available in the article.
Acknowledgments: The author is grateful to students Keerthi Krishnan and Ryan Kassab for technical assistance in preparation of the manuscript. The author acknowledges support from Schmid
College of Science and Technology at Chapman University for providing computing resources at the
Keck Center for Science and Engineering.
Conflicts of Interest: The authors declare that the research was conducted in the absence of any
commercial or financial relationship that could be construed as a potential conflict of interest. The

Int. J. Mol. Sci. 2022, 23, 2172

23 of 29

funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in
the writing of the manuscript, or in the decision to publish the results.

Abbreviations
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RBD
ACE2
NTD
RBD
CTD1
CTD2
FP
FPPR
HR1
CH
CD
HR2
TM
CT

Severe Acute Respiratory Syndrome
Receptor Binding Domain
Angiotensin-Converting Enzyme 2 (ACE2)
N-terminal domain
receptor-binding domain
C-terminal domain 1
C-terminal domain 2
fusion peptide
fusion peptide proximal region
heptad repeat 1
central helix region
connector domain
heptad repeat 2
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